Contents

Volume 45, Number A June Supplement 2007

Guest Editors Richard J. Powell, Anton N. Sidawy, Michael T. Watkins

Preface

Richard J. Powell, MD, Anton N. Sidawy, MD, and Michael T. Watkins, MD, Lebanon, NH; Washington, DC; and Boston, Mass

Chapter 1

Reviving the vascular surgeon–scientist: An interim assessment of the jointly sponsored Lifeline Foundation/National Heart, Lung, and Blood Institute William J. von Liebig Mentored Clinical Scientist Development (K08) Program

Robert W. Thompson, MD, Beth Schucker, MS, K. Craig Kent, MD, Alexander W. Clowes, MD, Larry W. Kraiss, MD, John A. Mannick, MD, and James S. T. Yao, MD, St. Louis, Mo; Bethesda, Md; New York, NY; Seattle, Wash; Salt Lake City, Utah; Boston, Mass; and Chicago, Ill

Chapter 2

Translational control in endothelial cells

Peter B. Brant-Zawadzki, MD, Douglas I. Schmid, MD, Huimao Jiang, MD, Andrew S. Weyrich, MD, Guy A. Zimmerman, MD, and Larry W. Kraiss, MD, Salt Lake City, Utah

Chapter 3

Smooth muscle cell signal transduction: Implications of vascular biology for vascular surgeons

Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M. Pimiento, MD, Stephen P. Malone, MD, Desarom Teso, MD, Jacek J. Paszkowiak, MD, Tormod S. Westvik, MD, Fabio A. Kudo, MD, PhD, Toshiya Nishibe, MD, PhD, and Alan Dardik, MD, PhD, New Haven, Waterbury, and West Haven, Conn; and Toyoake, Aichi, Japan

Cover Image: mTOR colocalizes with the Golgi apparatus. Colocalization of mTOR and the Golgi apparatus in Human Vascular Smooth Muscle Cells (HVSMC). Wild type mTOR (Flag-mTOR/pBJ5) was overexpressed in HVSMC by electroporation. The localization of mTOR in HVSMCs was determined by immunofluorescent staining with an anti-mTOR antibody (red, Cell Signalling (#2972), Danvers, MA). Anti-Golgin-97 antibody was used to detect the Golgi apparatus (green, Molecular Probes (A-21270), Leiden, The Netherlands). Shown is an image captured by scanning confocal microscopy. The yellow color shows colocalization of mTOR with Golgi apparatus. DAPI was used for DNA staining (nuclear compartment). (Robert J. Wagner, Eva M. Rzucidlo, M.D.)
CHAPTER 4

Regulation of vascular smooth muscle cell differentiation 25A
Eva M. Rzucidlo, MD, Kathleen A. Martin, PhD, and Richard J. Powell, MD, Lebanon, NH

CHAPTER 5

Integrin $\alpha_\beta_3$ as a target in the prevention of neointimal hyperplasia 33A
Taku Kokubo, MD, Hisashi Uchida, MD, and Eric T. Choi, MD, St. Louis, Mo

CHAPTER 6

Angiogenesis and vasculogenesis: Inducing the growth of new blood vessels and wound healing by stimulation of bone marrow–derived progenitor cell mobilization and homing 39A
Omaida C. Velazquez, MD, Philadelphia, Pa

CHAPTER 7

The chemokine system in arteriogenesis and hind limb ischemia 48A
Paula K. Shireman, MD, San Antonio, Tex

CHAPTER 8

Clinical, cellular, and molecular aspects of arterial calcification 57A
Raul J. Guzman, MD, Nashville, Tenn

CHAPTER 9

The role of nitric oxide in the pathophysiology of intimal hyperplasia 64A
Sadaf S. Ahanchi, MD, Nick D. Tsihlis, PhD, and Melina R. Kibbe, MD, Chicago, Ill

CHAPTER 10

Molecular engineering of vein bypass grafts 74A
Michael S. Conte, MD, Boston, Mass

CHAPTER 11

Genomic and proteomic determinants of lower extremity revascularization failure: Rationale and study design 82A
Peter R. Nelson, MD, Kerri A. O’Malley, PhD, Robert J. Feezor, MD, Lyle L. Moldawer, PhD, and James M. Seeger, MD, Gainesville, Fla

CHAPTER 12

Cytokines and the early vein graft: Strategies to enhance durability 92A
C. Keith Ozaki, MD, Gainesville, Fla
CHAPTER 13

Tissue engineering applications to vascular bypass graft development: The use of adipose-derived stem cells
Paul DiMuzio, MD, and Thomas Tulenko, PhD, Philadelphia, Pa

CHAPTER 14

Novel thromboresistant materials
Sumanas W. Jordan and Elliot L. Chaikof, MD, PhD, Atlanta, Ga

CHAPTER 15

Molecular characterization of post-thrombotic syndrome
Lornie J. Phillips II, MD, and Rajabrata Sarkar, MD, PhD, San Francisco, Calif

CHAPTER 16

Assessing the effectiveness of endografts: Clinical and experimental perspectives
Larisse K. Lee, MD, and Peter L. Faries, MD, New York, NY

CHAPTER 17

Impact of outcomes research on the management of vascular surgery patients
John E. Rectenwald, MD, and Gilbert R. Upchurch, Jr, MD, Ann Arbor, Mich

CHAPTER 18

Functional outcome of critical limb ischemia
Gregory J. Landry, MD, Portland, Ore

CHAPTER 19

Percutaneous treatment of peripheral vascular disease: The role of diabetes and inflammation
Louis L. Nguyen, MD, MBA, MPH, Boston, Mass

CHAPTER 20

Randomized clinical trials: How will results influence clinical practice in the management of symptomatic and asymptomatic extracranial carotid occlusive disease?
Robert W. Hobson II, MD, Newark, NJ